دورية أكاديمية
أعرض في EDS

Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer.

التفاصيل البيبلوغرافية
العنوان: Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer.
المؤلفون: Hendrixson M; Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA., Gladkiy Y; Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA., Thyagarajan A; Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA., Sahu RP; Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.
المصدر: Medical sciences (Basel, Switzerland) [Med Sci (Basel)] 2024 Apr 07; Vol. 12 (2). Date of Electronic Publication: 2024 Apr 07.
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629322 Publication Model: Electronic Cited Medium: Internet ISSN: 2076-3271 (Electronic) Linking ISSN: 20763271 NLM ISO Abbreviation: Med Sci (Basel) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Sorafenib*/therapeutic use , Lung Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use , Protein Kinase Inhibitors*/therapeutic use, Humans ; Animals ; Phenylurea Compounds/therapeutic use
مستخلص: Lung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.
References: Med Sci Monit. 2020 Apr 10;26:e922148. (PMID: 32275644)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
N Engl J Med. 2020 Oct 1;383(14):1328-1339. (PMID: 32997907)
Int J Mol Sci. 2018 Dec 21;20(1):. (PMID: 30577630)
Invest New Drugs. 2019 Oct;37(5):828-836. (PMID: 30456603)
J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. (PMID: 16507829)
Drug Deliv. 2021 Dec;28(1):2108-2118. (PMID: 34607478)
Biomed Pharmacother. 2024 Jan;170:116074. (PMID: 38147732)
Lancet. 2014 Jul 26;384(9940):319-28. (PMID: 24768112)
Cancer Growth Metastasis. 2014 Jun 19;7:27-32. (PMID: 25002816)
Expert Rev Anticancer Ther. 2014 Jul;14(7):807-15. (PMID: 24611674)
Cancer Res. 2004 Oct 1;64(19):7099-109. (PMID: 15466206)
Lung Cancer. 2017 Nov;113:79-84. (PMID: 29110854)
Cancer Drug Resist. 2022 Jun 23;5(3):749-761. (PMID: 36176764)
J Biochem Mol Toxicol. 2024 Jan;38(1):e23613. (PMID: 38229326)
N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514)
Nat Rev Drug Discov. 2006 Oct;5(10):835-44. (PMID: 17016424)
J Exp Clin Cancer Res. 2022 Jan 3;41(1):3. (PMID: 34980204)
Oncol Lett. 2020 Jul;20(1):346-356. (PMID: 32537024)
Expert Opin Investig Drugs. 2012 Sep;21(9):1417-26. (PMID: 22725255)
Cancer Manag Res. 2020 Jul 28;12:6493-6509. (PMID: 32801888)
Int J Cancer. 2017 Aug 1;141(3):428-436. (PMID: 28247946)
Int J Mol Sci. 2022 Jun 17;23(12):. (PMID: 35743223)
Lancet Oncol. 2019 Aug;20(8):1098-1108. (PMID: 31255490)
J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. (PMID: 28515157)
Eur J Cancer. 2009 Sep;45(14):2473-87. (PMID: 19596191)
J Hematol Oncol. 2023 Apr 17;16(1):40. (PMID: 37069698)
Int J Nanomedicine. 2023 May 18;18:2659-2676. (PMID: 37223276)
Pharmacogenet Genomics. 2017 Jun;27(6):240-246. (PMID: 28362716)
Expert Opin Pharmacother. 2014 Dec;15(18):2693-708. (PMID: 25381900)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
Cancer Sci. 2017 Nov;108(11):2265-2272. (PMID: 28846180)
Hypoxia (Auckl). 2015 Dec 11;3:83-92. (PMID: 27774485)
Clin Cancer Res. 2013 Dec 15;19(24):6967-75. (PMID: 24166906)
Cancer Discov. 2011 Jun;1(1):44-53. (PMID: 22586319)
Front Pharmacol. 2023 Jun 07;14:1207496. (PMID: 37351514)
Cancer Med. 2020 Jul;9(14):4991-5007. (PMID: 32436621)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Int J Mol Sci. 2020 Nov 12;21(22):. (PMID: 33198218)
J Clin Oncol. 2008 Jul 20;26(21):3552-9. (PMID: 18506026)
Oncol Lett. 2020 Jan;19(1):323-333. (PMID: 31897145)
J Clin Oncol. 2016 Oct 20;34(30):3638-3647. (PMID: 27480147)
Oncol Rep. 2019 Jul;42(1):231-242. (PMID: 31059070)
Med Clin North Am. 2019 May;103(3):463-473. (PMID: 30955514)
Cancer Res. 2023 Dec 1;83(23):3940-3955. (PMID: 37713596)
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. (PMID: 31378236)
Clin Cancer Res. 2013 Feb 1;19(3):743-51. (PMID: 23224737)
Hepatology. 2014 Apr;59(4):1435-47. (PMID: 24242874)
BMC Cancer. 2023 Dec 6;23(1):1198. (PMID: 38057830)
N Engl J Med. 2007 Jan 11;356(2):125-34. (PMID: 17215530)
J Thorac Oncol. 2015 Dec;10(12):1745-53. (PMID: 26743856)
Acta Pharmacol Sin. 2017 May;38(5):614-622. (PMID: 28344323)
N Engl J Med. 2017 Jun 22;376(25):2415-2426. (PMID: 28636851)
Pharm Res. 2020 Mar 12;37(3):67. (PMID: 32166411)
Contemp Oncol (Pozn). 2016;20(1):33-8. (PMID: 27095937)
معلومات مُعتمدة: R21 ES033806 United States ES NIEHS NIH HHS
فهرسة مساهمة: Keywords: cell signaling pathway; non-small cell lung cancer; sorafenib; targeted therapy
المشرفين على المادة: 9ZOQ3TZI87 (Sorafenib)
0 (Antineoplastic Agents)
0 (Protein Kinase Inhibitors)
0 (Phenylurea Compounds)
تواريخ الأحداث: Date Created: 20240423 Date Completed: 20240429 Latest Revision: 20240515
رمز التحديث: 20240515
مُعرف محوري في PubMed: PMC11036230
DOI: 10.3390/medsci12020020
PMID: 38651414
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-3271
DOI:10.3390/medsci12020020